Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Euronext Paris  >  Sanofi    SAN   FR0000120578

SANOFI

(SAN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
04/08/2021 04/09/2021 04/12/2021 04/13/2021 04/14/2021 Date
84.71(c) 85.06(c) 84.69(c) 84.07(c) 84.43 Last
1 348 869 1 486 808 1 251 699 2 044 073 322 157 Volume
+0.70% +0.41% -0.43% -0.73% +0.43% Change
More quotes
Financials
Sales 2021 36 815 M 44 053 M 44 053 M
Net income 2021 5 852 M 7 003 M 7 003 M
Net Debt 2021 7 064 M 8 453 M 8 453 M
P/E ratio 2021 17,9x
Yield 2021 3,90%
Sales 2022 38 935 M 46 590 M 46 590 M
Net income 2022 6 983 M 8 356 M 8 356 M
Net Debt 2022 3 489 M 4 175 M 4 175 M
P/E ratio 2022 15,0x
Yield 2022 4,13%
Capitalization 105 B 125 B 126 B
EV / Sales 2021 3,04x
EV / Sales 2022 2,79x
Nbr of Employees 99 412
Free-Float 88,7%
More Financials
Company
Sanofi is the largest European pharmaceutical group. Net sales by family of products break down as follows: - pharmaceutical products (71.2%): prescription drugs in the areas of general medicine (57.3% of net sales; mainly for the treatment of diabetes and cardiovascular diseases) and specialty medicine (42.7%; for the treatment of multiple sclerosis, neurological diseases, inflammatory diseases, autoimmune... 
Sector
Pharmaceuticals
Calendar
04/28Earnings Release
More about the company
Notations Surperformance© of Sanofi
Trading Rating : Investor Rating :
More Ratings
All news about SANOFI
04/13C4X DISCOVERY  : Up to EUR414 million Exclusive Worldwide Licensing Agreement wi..
AQ
04/13SWEDISH ORPHAN BIOVITRUM  : Sobi Doses First Patient In Phase 3 Trial Of Pediatr..
MT
04/13SWEDISH ORPHAN BIOVITRUM  : First patient dosed in phase 3 XTEND-Kids study with..
AQ
04/13SANOFI  : Declares Kiadis Offer Unconditional, All Offer Conditions Now Satisfie..
MT
04/13SANOFI  : Declares Offer for Immunotherapy Company Kiadis Unconditional
MT
04/13PRESS RELEASE : Evotec launches 'beLAB2122', translating academic innovation fro..
DJ
04/12French Pharma Firm Sanofi to Build $476 Million Vaccine Production Center in ..
MT
04/12SANOFI  : Buy rating from Goldman Sachs
MD
04/12SHENZHEN HEPALINK PHARMACEUTICAL  : Unit Sells Entire Stake in Kymab Group to Sa..
MT
04/12SANOFI  : to Invest $475 Million for Vaccine Production Site in Singapore
MT
04/12SANOFI  : to create 'cutting-edge' vaccine factory in Singapore
AQ
04/12C4X DISCOVERY  : Signs $492 Million Exclusive Licensing Deal With Sanofi
MT
04/12SANOFI  : Invests $475.5 Million to Build Vaccine Production Site in Singapore
MT
04/12Sanofi to Invest in Vaccine Production Site in Singapore
DJ
04/12C4X Discovery Shares Jump on Sanofi Licensing Agreement
DJ
More news
News in other languages on SANOFI
04/13DGAP-NAV  : Effecten-Spiegel AG: Net Asset Value
04/13LES MARCHÉS EN ACTION  : Emission du 13 Avril 2021
04/13ENGIE, plus forte baisse du CAC 40 à la mi-séance du mardi 13 avril 2021
04/13SANOFI  : plus de 95% de Kiadis détenus à l'issue de l'offre
04/13BRUSSELS STOCK EXCHANGE : Neutrale start Bel20 voorzien
More news
Analyst Recommendations on SANOFI
More recommendations
Stock Trading Strategies
SANOFI - 04/12
No turn-around in sight
BUY
More Stock Trading Analysis
Chart SANOFI
Duration : Period :
Sanofi Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SANOFI
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 26
Average target price 100,61 €
Last Close Price 84,07 €
Spread / Highest target 39,2%
Spread / Average Target 19,7%
Spread / Lowest Target -16,7%
EPS Revisions
Managers and Directors
NameTitle
Paul Hudson Chief Executive Officer & Director
Jean-Baptiste Chasseloup de Chatillon Chief Financial Officer & Executive Vice President
Serge Weinberg Chairman
John C. Reed EVP & Global Head-Research & Development
Nestle Frank Global Head-Immunology Therapeutic Research Area
Sector and Competitors
1st jan.Capitalization (M$)
SANOFI6.82%125 269
JOHNSON & JOHNSON1.33%424 524
ROCHE HOLDING AG-0.95%286 521
PFIZER INC.0.43%204 161
NOVARTIS AG-4.61%197 437
MERCK & CO., INC.-6.56%193 164